Recovery or Improvement of symptoms such as Insomnia, social deprivation, lethargy, self-confidence loss, depression, mental disorders, sexual drive loss, concentration loss.
Active ingridient of CareTropin is Somatropin, a growth hormone.
Growth hormone (GH) is a single polypeptide hormone secreted from the cells of the pituitary gland. The main effect of GH is to promote postnatal longitudinal growth. Hyposecretion of GH can lead to dwarfism. The growth-promoting effects of GH result from GH’s diverse and pleiotropic effects on cellular metabolism and differentiation. GH is known to regulate the lipid, carbohydrate, nitrogen, and mineral metabolism within a cell. Many of GH actions are mediated by the activation of insulin-like growth factor I (IGF-1)
► Pen-type syringe CARETROPIN
– Type: reusable, multidose, dose dialing
– Injection method: push type
– 1.5 mL cartridge: ISO 11608-3 compatible
► Current status CARETROPIN
– Approved in Dec. 2010 by Korean FDA
► Stability – Stable for 18 months (Stability test will be conducted at 24, 30 and 36 months)
Indication and usage of CARETROPIN
Adult patients: Treatment of adults with either childhood-onset or adult-onset growth hormone deficiency.